Abstract
Background:
Cost-impact models have indicated that in the USA, the use of antibiotic stewardship protocols based on procalcitonin (PCT) levels for patients with suspected acute respiratory tract infection results in cost savings. Our objective was to assess the cost impact of adopting PCT testing among patients with acute respiratory infections (ARI) from the perspective of a typical hospital system in urban China.
Methods:
To conduct an economic evaluation of PCT testing versus usual care we built a cost-impact model based on a previously published patient-level meta-analysis data of randomized trials including Chinese sites. The data were adapted to the China setting by applying the results to mean lengths of stay, costs, and practice patterns typically found in China. We estimated the annual ARI visit rate for the typical hospital system (assumed to be 1650 beds) and ARI diagnosis.
Results:
In the inpatient setting, the costs of PCT-guided care compared to usual care for a cohort of 16,405 confirmed ARI patients was almost 1.1 million Chinese yuan (CNY), compared to almost 1.8 million CNY for usual care, resulting in net savings of 721,563 CNY to a typical urban Chinese hospital system for 2015. In the ICU and outpatient settings, savings were 250,699 CNY and 2.4 million CNY, respectively. The overall annual net savings of PCT-guided care was nearly 3.4 million CNY.
Conclusions:
Substantial savings are associated with PCT protocols of ARI across common China hospital treatment settings mainly by direct reduction in unnecessary antibiotic utilization.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Support for this project was provided by Medical Affairs at BioMerieux.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010;28:1001–13.10.2165/11537410-000000000-00000Search in Google Scholar PubMed
2. Assasi N, Schwartz L, Tarride JE, Goeree R, Xie F. Economic evaluations conducted for assessment of genetic testing technologies: a systematic review. Genet Test Mol Biomarkers 2012;16:1322–35.10.1089/gtmb.2012.0178Search in Google Scholar PubMed
3. Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 2010;11:1573–90.10.2217/pgs.10.145Search in Google Scholar PubMed
4. Chowdhury P, Kehl D, Choudhary R, Maisel A. The use of biomarkers in the patient with heart failure. Curr Cardiol Rep 2013;15:372.10.1007/s11886-013-0372-4Search in Google Scholar PubMed
5. Diop D. Maximizing the quality and cost-effectiveness of cardiac care with laboratory technology and process improvements. J Cardiovasc Manag 2003;14:19–23.Search in Google Scholar
6. Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 2012;141:1063–73.10.1378/chest.11-2430Search in Google Scholar PubMed
7. Shen B, Hwang J. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin Pharmacol Ther 2010;88:754–6.10.1038/clpt.2010.236Search in Google Scholar PubMed
8. Wong W. A health plan’s integration of molecular diagnostics and the impact on treatment pathways for quality care. Manag Care 2008;17(7 Suppl 7):13–6; discussion 7–8.Search in Google Scholar
9. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013;19:216–28.10.1097/MCP.0b013e32835f27beSearch in Google Scholar PubMed
10. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556–73.10.1183/09031936.00166106Search in Google Scholar PubMed
11. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14:203.10.1186/cc8155Search in Google Scholar PubMed PubMed Central
12. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013;50: 23–36.10.3109/10408363.2013.764490Search in Google Scholar PubMed PubMed Central
13. File TM, Jr. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med 2011;32:417–30.10.1016/j.ccm.2011.05.011Search in Google Scholar PubMed PubMed Central
14. Gerber JS, Prasad PA, Fiks AG, Localio AR, Grundmeier RW, Bell LM, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. J Am Med Assoc 2013;309:2345–52.10.1001/jama.2013.6287Search in Google Scholar PubMed
15. Gjelstad S, Hoye S, Straand J, Brekke M, Dalen I, Lindbaek M. Improving antibiotic prescribing in acute respiratory tract infections: cluster randomised trial from Norwegian general practice (prescription peer academic detailing (Rx-PAD) study). Br Med J 2013;347:f4403.10.1136/bmj.f4403Search in Google Scholar PubMed PubMed Central
16. Lippi G, Meschi T, Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives. Eur J Intern Med 2011;22:460–5.10.1016/j.ejim.2011.02.023Search in Google Scholar PubMed
17. Luyt CE, Combes A, Trouillet JL, Chastre J. Biomarkers to optimize antibiotic therapy for pneumonia due to multidrug-resistant pathogens. Clin Chest Med 2011;32:431–8.10.1016/j.ccm.2011.05.004Search in Google Scholar PubMed
18. Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care 2008;12(Suppl 6):S5.10.1186/cc7028Search in Google Scholar PubMed PubMed Central
19. Mitsuma SF, Mansour MK, Dekker JP, Kim J, Rahman MZ, Tweed-Kent A, et al. Promising new assays and technologies for the diagnosis and management of infectious diseases. Clin Infect Dis 2013;56:996–1002.10.1093/cid/cis1014Search in Google Scholar PubMed PubMed Central
20. O’Brien DJ, Gould IM. Maximizing the impact of antimicrobial stewardship: the role of diagnostics, national and international efforts. Curr Opin Infect Dis 2013;26:352–8.10.1097/QCO.0b013e3283631046Search in Google Scholar PubMed
21. Reinhart K, Hartog CS. Biomarkers as a guide for antimicrobial therapy. Int J Antimicrob Agents 2010;36(Suppl 2):S17–21.10.1016/j.ijantimicag.2010.11.009Search in Google Scholar PubMed
22. Schuetz P, Christ-Crain M, Muller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:578–85.10.1097/MCC.0b013e3282c9ac2aSearch in Google Scholar PubMed
23. Schuetz P, Haubitz S, Mueller B. Do sepsis biomarkers in the emergency room allow transition from bundled sepsis care to personalized patient care? Curr Opin Crit care 2012;18:341–9.10.1097/MCC.0b013e328354b2c8Search in Google Scholar
24. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013;26:159–67.10.1097/QCO.0b013e32835d0becSearch in Google Scholar
25. Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in community-acquired pneumonia: a state-of-the-art review. Clinics (Sao Paulo) 2012;67:1321–5.10.6061/clinics/2012(11)17Search in Google Scholar
26. Upadhyay S, Niederman MS. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am 2013;27:19–31.10.1016/j.idc.2012.11.003Search in Google Scholar PubMed
27. Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008;29:591–603, vii.10.1016/j.ccm.2008.07.001Search in Google Scholar PubMed
28. Vincent JL, Beumier M. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther 2013;11:265–75.10.1586/eri.13.9Search in Google Scholar PubMed
29. Aabenhus R, Jensen JU. Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? Prim Care Respir J 2011;20:360–7.10.4104/pcrj.2011.00064Search in Google Scholar PubMed PubMed Central
30. Fazili T, Endy T, Javaid W, Maskey M. Role of procalcitonin in guiding antibiotic therapy. Am J Health Syst Pharm 2012;69:2057–61.10.2146/ajhp110736Search in Google Scholar PubMed
31. Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother 2012;67:2560–9.10.1093/jac/dks265Search in Google Scholar PubMed
32. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 2012;73:221–7.10.1016/j.diagmicrobio.2012.05.002Search in Google Scholar PubMed
33. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012;55:651–62.10.1093/cid/cis464Search in Google Scholar
34. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9:CD007498.10.1002/14651858.CD007498.pub2Search in Google Scholar
35. Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, et al. Influence of procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection: insight from the observational multicentric ProREAL surveillance. Eur J Clin Microbiol Infect Dis 2013;32:51–60.10.1007/s10096-012-1713-8Search in Google Scholar
36. Geiser MM. Procalcitonin Testing in the Puzzle of Sepsis. BioMerieux Report, 2013.Search in Google Scholar
37. Soni N, Samson D, Galaydick J, Vats V, Huang E, Aronson N, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 2013;8:530–40.10.1002/jhm.2067Search in Google Scholar
38. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:426–35.10.1016/S1473-3099(12)70323-7Search in Google Scholar
39. Wu MH, Lin CC, Huang SL, Shih HM, Wang CC, Lee CC, et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta-analysis. Influenza Other Respir Viruses 2013;7:349–55.10.1111/j.1750-2659.2012.00386.xSearch in Google Scholar PubMed PubMed Central
40. Yu CW, Juan LI, Wu MH, Shen CJ, Wu JY, Lee CC. Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin, C-reactive protein and white blood cell count for suspected acute appendicitis. Br J Surg 2013;100:322–9.10.1002/bjs.9008Search in Google Scholar PubMed
41. Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community-acquired pneumonia–a systematic review. Dan Med J 2012;59:A4357.Search in Google Scholar
42. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract 2005;6:34.10.1186/1471-2296-6-34Search in Google Scholar PubMed PubMed Central
43. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168:2000–7; discussion 7–8.10.1001/archinte.168.18.2000Search in Google Scholar PubMed
44. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010;8:575–87.10.1586/eri.10.25Search in Google Scholar PubMed
45. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322–31.10.1001/archinternmed.2011.318Search in Google Scholar PubMed
46. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37:497–507.10.1007/s15010-009-9034-2Search in Google Scholar PubMed
47. Wolff M, Bouadma L. What procalcitonin brings to management of sepsis in the ICU. Crit Care 2010;14:1007.10.1186/cc9330Search in Google Scholar PubMed PubMed Central
48. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011;53:379–87.10.1093/cid/cir408Search in Google Scholar PubMed
49. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715–22.10.1001/archinternmed.2012.770Search in Google Scholar PubMed
50. Deliberato RO, Marra AR, Sanches PR, Martino MD, Ferreira CE, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Micr Infect Dis 2013;76:266–71.10.1016/j.diagmicrobio.2013.03.027Search in Google Scholar PubMed
51. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792–9.10.1097/CCM.0b013e31821201a5Search in Google Scholar PubMed
52. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health 2013;8:1297–371.10.1002/14651858.CD007498.pub2Search in Google Scholar PubMed PubMed Central
53. Soni N, Samson D, Galaydick J, Vats V, Pitrak D, Aronson N. Procalcitonin-guided antibiotic therapy. Comparative effectiveness review No. 78. AHRQ Publication No. 12(13)-EHC124-EF. Rockville, MD: Agency for Healthcare Research and Quality: Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I, 2012.Search in Google Scholar
54. Chen M, Wang L, Chen W, Zhang L, Jiang H, Mao W. Does economic incentive matter for rational use of medicine? China’s experience from the essential medicines program. PharmacoEconomics 2014;32:245–55.10.1007/s40273-013-0068-zSearch in Google Scholar PubMed
55. Thomson S, Osborn R, Squires D, Reed SJ. International Profiles of Health Care Systems, 2011. The Commonwealth Fund, November 2011.Search in Google Scholar
56. WHO. Chronic Respiratory Diseases. Geneva, Switzerland: World Health Organization, 2005.Search in Google Scholar
57. LIU Yue-hua WJ-h, Zhang Jie. Emergency Disease spectrum in China: based on Hospital Database From Beijing. Beijing, China: Tsinghua University, May 2015.10.1016/j.jval.2015.03.509Search in Google Scholar
58. He R, Luo B, Hu C, Li Y, Niu R. Differences in distribution and drug sensitivity of pathogens in lower respiratory tract infections between general wards and RICU. J Thorac Dis 2014;6:1403–10.Search in Google Scholar
59. Wang J, Wang Q, Bi Z. [A surveillance on acute respiratory infection]. Zhonghua liu xing bing xue za zhi 1994;15:141–4.Search in Google Scholar
60. Zhang Y, Yao Z, Zhan S, Yang Z, Wei D, Zhang J, et al. Disease burden of intensive care unit-acquired pneumonia in China: a systematic review and meta-analysis. Intern J Infect Dis 2014;29:84–90.10.1016/j.ijid.2014.05.030Search in Google Scholar PubMed
61. Cheng A, Ren N, Wen X. A nosocomial infection point-prevalence survey: results and analysis of 193 Hospitals in China in 2001. Chin J Nosocomiol 2002;12:561 – 3.Search in Google Scholar
62. Fu C, Yang J. Influence of carrying out zero price addition policy of drugs on public hospital expenses in shenzhen. Chinese Hospital Management 2013;33:4–6.Search in Google Scholar
63. He S, Chen B, Li W, Yan J, Chen L, Wang X, et al. Ventilator-associated pneumonia after cardiac surgery: a meta-analysis and systematic review. J Thorac Cardiovasc Surg 2014;148:3148–55.e1–5.10.1016/j.jtcvs.2014.07.107Search in Google Scholar PubMed
64. Zhang X, Wang R, Di X, Liu B, Liu Y. Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis 2014;6:134–42.Search in Google Scholar
65. Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff (Millwood) 2012;31:1075–82.10.1377/hlthaff.2010.0965Search in Google Scholar PubMed
66. Huang HH, Zhang YY, Xiu QY, Zhou X, Huang SG, Lu Q, et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis 2006;25:369–74.10.1007/s10096-006-0146-7Search in Google Scholar PubMed
67. Liu YN, Cao B, Wang H, Chen LA, She DY, Zhao TM, et al. [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities]. Zhonghua jie he he hu xi za zhi 2012;35:739–46.Search in Google Scholar
68. He LX. [Guidelines for the diagnosis and treatment of community-acquired pneumonia: learning and practicing]. Zhonghua jie he he hu xi za zhi 2006;29:649–50.Search in Google Scholar
69. Li C, Ren N, Wen X, Zhou P, Huang X, Gong R, et al. Changes in antimicrobial use prevalence in China: results from five point prevalence studies. PLoS One 2013;8:e82785.10.1371/journal.pone.0082785Search in Google Scholar PubMed PubMed Central
70. Ding JG, Sun QF, Li KC, Zheng MH, Miao XH, Ni W, et al. Retrospective analysis of nosocomial infections in the intensive care unit of a tertiary hospital in China during 2003 and 2007. BMC Infect Dis 2009;9:115.10.1186/1471-2334-9-115Search in Google Scholar PubMed PubMed Central
71. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–55.10.1164/rccm.200703-456SOSearch in Google Scholar PubMed
72. Gao J, Prasad N. Chronic obstructive pulmonary disease in China: the potential role of indacaterol. J Thorac Dis 2013;5:549–58.Search in Google Scholar
73. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27–72.10.1086/511159Search in Google Scholar PubMed PubMed Central
74. Liu Y, Chen M, Zhao T, Wang H, Wang R, Cai B, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC Infect Dis 2009;9:31.10.1186/1471-2334-9-31Search in Google Scholar PubMed PubMed Central
75. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011;16:819–24.10.1111/j.1440-1843.2011.01978.xSearch in Google Scholar PubMed
76. Schuetz P, Briel M, Christ-Crain M, Wolbers M, Stolz D, Tamm M, et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections (Protocol). Cochrane Database Syst Rev 2008. Art. No.: CD007498.10.1002/14651858.CD007498Search in Google Scholar
77. Cai BQ, Cai SX, Chen RC, Cui LY, Feng YL, Gu YT, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People’s Republic of China. Int J Chron Obstruct Pulmon Dis 2014;9:381–95.10.2147/COPD.S58454Search in Google Scholar PubMed PubMed Central
78. Li ZP, Huang JQ, Tang KJ. [Retrospective studies on 713 cases chronic obstructive pulmonary disease]. Zhonghua liu xing bing xue za zhi 2003;24:722–4.Search in Google Scholar
79. Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015;53:583–92.10.1515/cclm-2014-1015Search in Google Scholar PubMed
80. van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ, Polderman KH. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 2003;7:R184–90.10.1186/cc2388Search in Google Scholar PubMed PubMed Central
81. Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29:579–86.10.1007/s11606-013-2679-7Search in Google Scholar PubMed PubMed Central
82. Lee M, Snyder A. The role of procalcitonin in community-acquired pneumonia: a literature review. Adv Emerg Nurs J 2012;34:259–71.10.1097/TME.0b013e318261338dSearch in Google Scholar PubMed
83. Bishop BM, Bon JJ, Trienski TL, Pasquale TR, Martin BR, File TM, Jr. Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Ann Pharmacother 2014;48:577–83.10.1177/1060028014520957Search in Google Scholar PubMed
84. Cohen B, Larson EL, Stone PW, Neidell M, Glied SA. Factors associated with variation in estimates of the cost of resistant infections. Med Care 2010;48:767–75.10.1097/MLR.0b013e3181e358b9Search in Google Scholar PubMed PubMed Central
©2017 Walter de Gruyter GmbH, Berlin/Boston